|Day's range||3.1000 - 3.1000|
IQVIA™ (NYSE: IQV), a leader in human data science, today announced the launch of Avacare Clinical Research Network™, a technology-based global site network that opens opportunities for more clinical trials at experienced clinical and research sites. Avacare’s unique analytical tools help sites in Avacare’s network match patients to clinical trials faster and more effectively.
Ari Bousbib has been the CEO of IQVIA Holdings Inc. (NYSE:IQV) since 2016. First, this article will compare CEO...
IQVIA (IQV) delivered earnings and revenue surprises of 1.16% and 1.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
IQVIA Reports Fourth-Quarter and Full-Year 2019 Results; Issues First-Quarter and Full-Year 2020 Guidance
IQVIA (IQV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IQVIA (IQV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
IQVIA™ (NYSE: IQV) today announced the launch of the FluSTAR mobile application to help consumers understand and track flu and cold severity this winter. IQVIA’s FluStar app uses near real-time updates complied at www.FluSTAR.com, for current illness information for every ZIP code in the country, accessible from any mobile device.
IQVIA™ (NYSE: IQV) announced today that its Linguamatics Natural Language Processing (NLP) platform has been selected as the winner in Questex’s 2019 Fierce Innovation Awards — LifeSciences Edition in the Data Analytics/Business Intelligence category. The Fierce Innovation Awards is a peer-reviewed awards program from the publisher of FierceBiotech and FiercePharma and recognizes IQVIA Linguamatics NLP platform as an industry-leading product.
IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), will announce its fourth-quarter and full-year 2019 financial results and issue 2020 guidance before the market opens on Wednesday, February 12, 2020. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.
Assistance Publique – Hôpitaux de Paris (AP-HP), Europe's leading clinical research center, joins IQVIA™, the global health technology and human data science company, to launch the Paris Prime Site for clinical trials. This AP-HP partnership represents IQVIA’s second Prime Site within France, as well as the 43rd globally, the 18th within Europe and largest research facility of its kind within that region.
IQVIA Holdings Inc. ("IQVIA") (NYSE: IQV) has been named to FORTUNE magazine’s "World’s Most Admired Companies" list. IQVIA has received this distinction every year, since its inception, following the merger between IMS Health and Quintiles in 2016. IQVIA is recognized in FORTUNE’s Healthcare: Pharmacy and Other Services category with high marks regarding efficient use of corporate assets, management quality, effectiveness in conducting business globally, and long-term investment value.
Solid technological suite, growth opportunities from emerging markets and efforts to boost its presence in real-world business are the major positives for IQVIA Holdings (IQV).
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...